SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-25-003078 to Liquidia Corp (LQDA) (CIK 0001819576) (LQDA)

Liquidia Corp (LQDA) (CIK 0001819576)
Date: March 21, 2025 · CIK: 0001819576 · Accession: 0000000000-25-003078

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-285923

Date
March 21, 2025
Author
Division of
Form
UPLOAD
Company
Liquidia Corp (LQDA) (CIK 0001819576)

Letter

Re: Liquidia Corp Registration Statement on Form S-3 Filed March 19, 2025 File No. 333-285923 Dear Roger Jeffs:

March 21, 2025

Roger Jeffs Chief Executive Officer Liquidia Corp 419 Davis Drive, Suite 100 Morrisville, NC 27560

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Andrew P. Gilbert

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 21, 2025

Roger Jeffs
Chief Executive Officer
Liquidia Corp
419 Davis Drive, Suite 100
Morrisville, NC 27560

 Re: Liquidia Corp
 Registration Statement on Form S-3
 Filed March 19, 2025
 File No. 333-285923
Dear Roger Jeffs:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Andrew P. Gilbert
</TEXT>
</DOCUMENT>